Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTZGGIVK)

DOT Name	NAD(P)H dehydrogenase 1 (NQO1)
Synonyms	EC 1.6.5.2; Azoreductase; DT-diaphorase; DTD; Menadione reductase; NAD(P)H:quinone oxidoreductase 1; Phylloquinone reductase; Quinone reductase 1; QR1
Gene Name	NQO1
UniProt ID	NQO1_HUMAN
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
PDB ID	1D4A; 1DXO; 1GG5; 1H66; 1H69; 1KBO; 1KBQ; 1QBG; 2F1O; 3JSX; 4CET; 4CF6; 5A4K; 5EA2; 5EAI; 5FUQ; 6FY4; 6LLC; 8C9J; 8OK0
EC Number	1.6.5.2
Pfam ID	PF02525
Sequence	MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKL KDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERV FIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFC GFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMK KEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK
Function	Flavin-containing quinone reductase that catalyzes two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species. Regulates cellular redox state primarily through quinone detoxification. Reduces components of plasma membrane redox system such as coenzyme Q and vitamin quinones, producing antioxidant hydroquinone forms. In the process may function as superoxide scavenger to prevent hydroquinone oxidation and facilitate excretion. Alternatively, can activate quinones and their derivatives by generating redox reactive hydroquinones with DNA cross-linking antitumor potential. Acts as a gatekeeper of the core 20S proteasome known to degrade proteins with unstructured regions. Upon oxidative stress, interacts with tumor suppressors TP53 and TP73 in a NADH-dependent way and inhibits their ubiquitin-independent degradation by the 20S proteasome.
KEGG Pathway	Ubiquinone and other terpenoid-quinone biosynthesis (hsa00130 ) Metabolic pathways (hsa01100 ) Biosynthesis of cofactors (hsa01240 ) Pathways in cancer (hsa05200 ) Chemical carcinogenesis - reactive oxygen species (hsa05208 ) Hepatocellular carcinoma (hsa05225 ) Fluid shear stress and atherosclerosis (hsa05418 )
Reactome Pathway	NFE2L2 regulating anti-oxidant/detoxification enzymes (R-HSA-9818027 ) Regulation of ornithine decarboxylase (ODC) (R-HSA-350562 )
BioCyc Pathway	MetaCyc:HS11566-MONOMER

Molecular Interaction Atlas (MIA) of This DOT

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DOT

This DOT Affected the Drug Response of 7 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Mitomycin	DMH0ZJE	Approved	NAD(P)H dehydrogenase 1 (NQO1) increases the response to substance of Mitomycin.	[77]
Warfarin	DMJYCVW	Approved	NAD(P)H dehydrogenase 1 (NQO1) affects the response to substance of Warfarin.	[78]
Nitrofurantoin	DM7PQIK	Approved	NAD(P)H dehydrogenase 1 (NQO1) increases the response to substance of Nitrofurantoin.	[79]
Nitrobenzanthrone	DMN6L70	Investigative	NAD(P)H dehydrogenase 1 (NQO1) increases the activity of Nitrobenzanthrone.	[84]
Aminohippuric acid	DMUN54G	Investigative	NAD(P)H dehydrogenase 1 (NQO1) affects the response to substance of Aminohippuric acid.	[85]
Dichloroindophenol	DMAEI51	Investigative	NAD(P)H dehydrogenase 1 (NQO1) increases the response to substance of Dichloroindophenol.	[87]
streptonigrin	DM0HOEA	Investigative	NAD(P)H dehydrogenase 1 (NQO1) increases the response to substance of streptonigrin.	[88]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

This DOT Affected the Regulation of Drug Effects of 1 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Tanespimycin	DMNLQHK	Phase 2	NAD(P)H dehydrogenase 1 (NQO1) increases the abundance of Tanespimycin.	[80]
------------------------------------------------------------------------------------

This DOT Affected the Biotransformations of 5 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Beta-lapachone	DMMI84K	Phase 2	NAD(P)H dehydrogenase 1 (NQO1) increases the reduction of Beta-lapachone.	[81]
PMID26882240-Compound-32	DMJS4RP	Patented	NAD(P)H dehydrogenase 1 (NQO1) increases the reduction of PMID26882240-Compound-32.	[82]
Geldanamycin	DMS7TC5	Discontinued in Phase 2	NAD(P)H dehydrogenase 1 (NQO1) increases the reduction of Geldanamycin.	[82]
CB1954	DMVP4YK	Discontinued in Phase 2	NAD(P)H dehydrogenase 1 (NQO1) increases the reduction of CB1954.	[83]
NAPQI	DM8F5LR	Investigative	NAD(P)H dehydrogenase 1 (NQO1) increases the reduction of NAPQI.	[86]
------------------------------------------------------------------------------------

97 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[1]
Ciclosporin	DMAZJFX	Approved	Ciclosporin decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[2]
Tretinoin	DM49DUI	Approved	Tretinoin decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[3]
Acetaminophen	DMUIE76	Approved	Acetaminophen decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[4]
Doxorubicin	DMVP5YE	Approved	Doxorubicin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[5]
Cisplatin	DMRHGI9	Approved	Cisplatin decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[6]
Estradiol	DMUNTE3	Approved	Estradiol decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[7]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[8]
Arsenic	DMTL2Y1	Approved	Arsenic decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[9]
Quercetin	DM3NC4M	Approved	Quercetin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[10]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[11]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[12]
Vorinostat	DMWMPD4	Approved	Vorinostat increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[13]
Carbamazepine	DMZOLBI	Approved	Carbamazepine affects the expression of NAD(P)H dehydrogenase 1 (NQO1).	[14]
Decitabine	DMQL8XJ	Approved	Decitabine increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[15]
Zoledronate	DMIXC7G	Approved	Zoledronate decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[16]
Menadione	DMSJDTY	Approved	Menadione increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[17]
Panobinostat	DM58WKG	Approved	Panobinostat increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[13]
Dexamethasone	DMMWZET	Approved	Dexamethasone increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[18]
Cannabidiol	DM0659E	Approved	Cannabidiol increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[19]
Bortezomib	DMNO38U	Approved	Bortezomib increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[20]
Hydroquinone	DM6AVR4	Approved	Hydroquinone increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[21]
Rosiglitazone	DMILWZR	Approved	Rosiglitazone increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[22]
Ethanol	DMDRQZU	Approved	Ethanol decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[23]
Aspirin	DM672AH	Approved	Aspirin increases the activity of NAD(P)H dehydrogenase 1 (NQO1).	[24]
Etoposide	DMNH3PG	Approved	Etoposide increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[25]
Irinotecan	DMP6SC2	Approved	Irinotecan decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[26]
Diclofenac	DMPIHLS	Approved	Diclofenac increases the activity of NAD(P)H dehydrogenase 1 (NQO1).	[27]
Sodium lauryl sulfate	DMLJ634	Approved	Sodium lauryl sulfate increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[28]
Cidofovir	DMA13GD	Approved	Cidofovir decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[6]
Simvastatin	DM30SGU	Approved	Simvastatin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[29]
Gemcitabine	DMSE3I7	Approved	Gemcitabine increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[30]
Mifepristone	DMGZQEF	Approved	Mifepristone decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[31]
Ifosfamide	DMCT3I8	Approved	Ifosfamide decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[6]
Clodronate	DM9Y6X7	Approved	Clodronate decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[6]
Sulindac	DM2QHZU	Approved	Sulindac increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[32]
Capsaicin	DMGMF6V	Approved	Capsaicin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[33]
Ibuprofen	DM8VCBE	Approved	Ibuprofen affects the expression of NAD(P)H dehydrogenase 1 (NQO1).	[34]
Daunorubicin	DMQUSBT	Approved	Daunorubicin decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[8]
Adefovir dipivoxil	DMMAWY1	Approved	Adefovir dipivoxil decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[6]
Rofecoxib	DM3P5DA	Approved	Rofecoxib affects the expression of NAD(P)H dehydrogenase 1 (NQO1).	[34]
Ampicillin	DMHWE7P	Approved	Ampicillin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[35]
Bosentan	DMIOGBU	Approved	Bosentan increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[36]
Isoniazid	DM5JVS3	Approved	Isoniazid increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[37]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Approved	Eicosapentaenoic acid/docosa-hexaenoic acid increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[38]
Hesperetin	DMKER83	Approved	Hesperetin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[39]
Lapatinib	DM3BH1Y	Approved	Lapatinib increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[40]
Benzoic acid	DMKB9FI	Approved	Benzoic acid increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[41]
Flurbiprofen	DMGN4BY	Approved	Flurbiprofen increases the activity of NAD(P)H dehydrogenase 1 (NQO1).	[27]
Sanguinarine	DMDINFS	Approved	Sanguinarine decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[8]
Roflumilast	DMPGHY8	Approved	Roflumilast increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[42]
Amoxicillin	DMUYNEI	Approved	Amoxicillin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[37]
Tacrine	DM51FY6	Approved	Tacrine decreases the activity of NAD(P)H dehydrogenase 1 (NQO1).	[43]
Tecfidera	DM2OVDT	Approved	Tecfidera increases the activity of NAD(P)H dehydrogenase 1 (NQO1).	[44]
Dicumarol	DMFQCB1	Approved	Dicumarol decreases the activity of NAD(P)H dehydrogenase 1 (NQO1).	[45]
Penicillin V	DMKVOYF	Approved	Penicillin V increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[35]
ARZOXIFENE	DMOKCVI	Approved	ARZOXIFENE increases the activity of NAD(P)H dehydrogenase 1 (NQO1).	[46]
Urethane	DM7NSI0	Phase 4	Urethane decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[47]
Isoflavone	DM7U58J	Phase 4	Isoflavone increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[48]
SNDX-275	DMH7W9X	Phase 3	SNDX-275 increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[13]
Resveratrol	DM3RWXL	Phase 3	Resveratrol decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[8]
Curcumin	DMQPH29	Phase 3	Curcumin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[49]
Fenretinide	DMRD5SP	Phase 3	Fenretinide affects the expression of NAD(P)H dehydrogenase 1 (NQO1).	[50]
HMPL-004	DM29XGY	Phase 3	HMPL-004 decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[51]
Bardoxolone methyl	DMODA2X	Phase 3	Bardoxolone methyl decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[51]
I3C	DMIGFOR	Phase 3	I3C increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[52]
EXISULIND	DMBY56U	Phase 3	EXISULIND increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[53]
Benzylpenicillin	DMS9503	Phase 3	Benzylpenicillin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[35]
Genistein	DM0JETC	Phase 2/3	Genistein decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[7]
Phenol	DM1QSM3	Phase 2/3	Phenol increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[55]
Tocopherol	DMBIJZ6	Phase 2	Tocopherol increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[29]
Belinostat	DM6OC53	Phase 2	Belinostat increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[13]
DNCB	DMDTVYC	Phase 2	DNCB increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[56]
phorbol 12-myristate 13-acetate	DMJWD62	Phase 2	phorbol 12-myristate 13-acetate increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[57]
PEITC	DMOMN31	Phase 2	PEITC increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[58]
Disulfiram	DMCL2OK	Phase 2 Trial	Disulfiram increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[41]
NVP-AUY922	DMTYXQF	Phase 2	NVP-AUY922 decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[59]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[60]
(+)-JQ1	DM1CZSJ	Phase 1	(+)-JQ1 increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[61]
Eugenol	DM7US1H	Patented	Eugenol increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[41]
PMID26560530-Compound-34	DMLGZPO	Patented	PMID26560530-Compound-34 increases the activity of NAD(P)H dehydrogenase 1 (NQO1).	[64]
Benzylcinnamate	DMD7Z3H	Patented	Benzylcinnamate increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[28]
MG-132	DMKA2YS	Preclinical	MG-132 increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[65]
Scriptaid	DM9JZ21	Preclinical	Scriptaid affects the expression of NAD(P)H dehydrogenase 1 (NQO1).	[66]
Taxifolin	DMQJSF9	Preclinical	Taxifolin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[67]
EMODIN	DMAEDQG	Terminated	EMODIN increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[68]
SB 203580	DMAET6F	Terminated	SB 203580 decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[69]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[70]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[66]
Milchsaure	DM462BT	Investigative	Milchsaure increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[41]
Sulforaphane	DMQY3L0	Investigative	Sulforaphane increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[71]
chloropicrin	DMSGBQA	Investigative	chloropicrin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[72]
Deguelin	DMXT7WG	Investigative	Deguelin increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[33]
3R14S-OCHRATOXIN A	DM2KEW6	Investigative	3R14S-OCHRATOXIN A decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[73]
Paraquat	DMR8O3X	Investigative	Paraquat decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[74]
Hexadecanoic acid	DMWUXDZ	Investigative	Hexadecanoic acid increases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[75]
D-glucose	DMMG2TO	Investigative	D-glucose decreases the expression of NAD(P)H dehydrogenase 1 (NQO1).	[76]
------------------------------------------------------------------------------------


⏷ Show the Full List of 97 Drug(s)

1 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Vanadate	DMQL0KF	Phase 3	Vanadate decreases the stability of NAD(P)H dehydrogenase 1 (NQO1).	[54]
------------------------------------------------------------------------------------

2 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
TAK-243	DM4GKV2	Phase 1	TAK-243 increases the sumoylation of NAD(P)H dehydrogenase 1 (NQO1).	[62]
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 increases the phosphorylation of NAD(P)H dehydrogenase 1 (NQO1).	[63]
------------------------------------------------------------------------------------

References

1	Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
2	Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
3	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
4	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
5	Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
6	Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
7	Phytoestrogens modulate the expression of 17alpha-estradiol metabolizing enzymes in cultured MCF-7 cells. Adv Exp Med Biol. 2008;617:625-32.
8	High-throughput library screening identifies two novel NQO1 inducers in human lung cells. Am J Respir Cell Mol Biol. 2012 Mar;46(3):365-71.
9	Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
10	Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett. 2001 Feb 3;119(1):49-57.
11	Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009 May;8(5):1197-206.
12	Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
13	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
14	Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
15	The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
16	Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
17	Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
18	Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
19	Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
20	The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
21	A realistic in vitro exposure revealed seasonal differences in (pro-)inflammatory effects from ambient air in Fribourg, Switzerland. Inhal Toxicol. 2018 Jan;30(1):40-48. doi: 10.1080/08958378.2018.1441926. Epub 2018 Mar 6.
22	PPARgama activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp Neurol. 2014 Mar;253:16-27.
23	Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
24	Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide. Chem Res Toxicol. 2012 Dec 17;25(12):2725-36.
25	Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol. 2018 Apr;92(4):1507-1524.
26	Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
27	Aspirin-like drugs can protect human T lymphocytes against benzoquinone cytotoxicity: evidence for a NAD(P)H:quinone reductase-dependent mechanism. Arch Toxicol. 1995;69(10):684-9.
28	A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
29	Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
30	CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-B signaling pathway. Cell Biol Toxicol. 2023 Aug;39(4):1549-1560. doi: 10.1007/s10565-022-09746-w. Epub 2022 Aug 1.
31	Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
32	Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
33	Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615. doi: 10.1007/s00204-020-02970-5. Epub 2021 Jan 29.
34	Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
35	Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):283-92.
36	Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
37	Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
38	Astaxanthin and omega-3 fatty acids individually and in combination protect against oxidative stress via the Nrf2-ARE pathway. Food Chem Toxicol. 2013 Dec;62:869-75.
39	Hesperetin relieves cisplatin-induced acute kidney injury by mitigating oxidative stress, inflammation and apoptosis. Chem Biol Interact. 2019 Aug 1;308:269-278.
40	P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
41	Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
42	Roflumilast protects from cisplatin-induced testicular toxicity in male rats and enhances its cytotoxicity in prostate cancer cell line. Role of NF-B-p65, cAMP/PKA and Nrf2/HO-1, NQO1 signaling. Food Chem Toxicol. 2021 May;151:112133. doi: 10.1016/j.fct.2021.112133. Epub 2021 Mar 20.
43	Reduction and scavenging of chemically reactive drug metabolites by NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 and variability in hepatic concentrations. Chem Res Toxicol. 2018 Feb 19;31(2):116-126.
44	Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs. 2005 Feb;16(2):167-74.
45	NRH:quinone oxidoreductase2 (NQO2). Chem Biol Interact. 2000 Dec 1;129(1-2):99-112.
46	Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms. Mol Cancer Ther. 2007 Sep;6(9):2418-28.
47	Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
48	Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells. J Nutr. 2006 Jan;136(1):75-82.
49	Curcumin analog 1, 5-bis (2-trifluoromethylphenyl)-1, 4-pentadien-3-one exhibits enhanced ability on Nrf2 activation and protection against acrolein-induced ARPE-19 cell toxicity. Toxicol Appl Pharmacol. 2013 Nov 1;272(3):726-35.
50	4-HPR modulates gene expression in ovarian cells. Int J Cancer. 2006 Sep 1;119(5):1005-13. doi: 10.1002/ijc.21797.
51	Mapping the dynamics of Nrf2 antioxidant and NFB inflammatory responses by soft electrophilic chemicals in human liver cells defines the transition from adaptive to adverse responses. Toxicol In Vitro. 2022 Oct;84:105419. doi: 10.1016/j.tiv.2022.105419. Epub 2022 Jun 17.
52	Combination of xanthohumol and phenethyl isothiocyanate inhibits NF-B and activates Nrf2 in pancreatic cancer cells. Toxicol In Vitro. 2020 Jun;65:104799. doi: 10.1016/j.tiv.2020.104799. Epub 2020 Feb 15.
53	Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
54	Modulation of NAD(P)H:quinone oxidoreductase by vanadium in human hepatoma HepG2 cells. Toxicol In Vitro. 2010 Sep;24(6):1554-61.
55	Human NAD(P)H:quinone oxidoreductase induction in human hepatoma cells after exposure to industrial acrylates, phenolics, and metals. Drug Metab Dispos. 1997 Feb;25(2):175-81.
56	MIP-1beta, a novel biomarker for in vitro sensitization test using human monocytic cell line. Toxicol In Vitro. 2006 Aug;20(5):736-42.
57	Nrf2 expression and activity in human T lymphocytes: stimulation by T cell receptor activation and priming by inorganic arsenic and tert-butylhydroquinone. Free Radic Biol Med. 2014 Jun;71:133-145. doi: 10.1016/j.freeradbiomed.2014.03.006. Epub 2014 Mar 13.
58	Phytochemical-induced changes in gene expression of carcinogen-metabolizing enzymes in cultured human primary hepatocytes. Xenobiotica. 2004 Jul;34(7):619-32.
59	Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells. 2019 Jul 31;8(8):806. doi: 10.3390/cells8080806.
60	Profiles of antioxidant/electrophile response element (ARE/EpRE) nuclear protein binding and c-Ha-ras transactivation in vascular smooth muscle cells treated with oxidative metabolites of benzo[a]pyrene. Biochem Pharmacol. 2000 Nov 1;60(9):1285-96.
61	Bromodomain and extraterminal proteins suppress NF-E2-related factor 2-mediated antioxidant gene expression. J Immunol. 2014 May 15;192(10):4913-4920.
62	Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
63	Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
64	Protection of retinal pigment epithelial cells from oxidative damage by oltipraz, a cancer chemopreventive agent. Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3550-4.
65	Differential effects of arsenic species on Nrf2 and Bach1 nuclear localization in cultured hepatocytes. Toxicol Appl Pharmacol. 2021 Feb 15;413:115404. doi: 10.1016/j.taap.2021.115404. Epub 2021 Jan 9.
66	Enrichment of Nur77 mediated by retinoic acid receptor leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors. Hepatology. 2011 Mar;53(3):865-74. doi: 10.1002/hep.24101. Epub 2011 Feb 11.
67	The chemopreventive effect of taxifolin is exerted through ARE-dependent gene regulation. Biol Pharm Bull. 2007 Jun;30(6):1074-9.
68	Inhibition of CYP3A4 enhances aloe-emodin induced hepatocyte injury. Toxicol In Vitro. 2022 Mar;79:105276. doi: 10.1016/j.tiv.2021.105276. Epub 2021 Dec 4.
69	Quercetin inhibits LPS-induced adhesion molecule expression and oxidant production in human aortic endothelial cells by p38-mediated Nrf2 activation and antioxidant enzyme induction. Redox Biol. 2016 Oct;9:104-113.
70	Bisphenol A activates the Nrf1/2-antioxidant response element pathway in HEK 293 cells. Chem Res Toxicol. 2013 Mar 18;26(3):498-506.
71	Effects of antioxidants on oxidative stress and inflammatory responses of human bronchial epithelial cells exposed to particulate matter and cigarette smoke extract. Toxicol In Vitro. 2020 Sep;67:104883. doi: 10.1016/j.tiv.2020.104883. Epub 2020 May 6.
72	Gene expressions changes in bronchial epithelial cells: markers for respiratory sensitizers and exploration of the NRF2 pathway. Toxicol In Vitro. 2014 Mar;28(2):209-17.
73	Persistence of epigenomic effects after recovery from repeated treatment with two nephrocarcinogens. Front Genet. 2018 Dec 3;9:558.
74	Hydrogen peroxide responsive miR153 targets Nrf2/ARE cytoprotection in paraquat induced dopaminergic neurotoxicity. Toxicol Lett. 2014 Aug 4;228(3):179-91.
75	Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation. Toxicol Appl Pharmacol. 2018 Dec 1;360:18-29.
76	Protective effect of solanesol in glucose-induced hepatocyte injury: Mechanistic insights on oxidative stress and mitochondrial preservation. Chem Biol Interact. 2023 Sep 25;383:110676. doi: 10.1016/j.cbi.2023.110676. Epub 2023 Aug 14.
77	Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
78	Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. Eur J Clin Pharmacol. 2015 Oct;71(10):1229-36. doi: 10.1007/s00228-015-1915-y. Epub 2015 Aug 11.
79	Roles of DT diaphorase in the genotoxicity of nitroaromatic compounds in human and fish cell lines. J Toxicol Environ Health. 1997 Oct 10;52(2):137-48. doi: 10.1080/00984109708984057.
80	Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells. J Pharmacol Exp Ther. 2011 Mar;336(3):874-80.
81	Human NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated inactivation of reactive quinoneimine metabolites of diclofenac and mefenamic acid. Chem Res Toxicol. 2014 Apr 21;27(4):576-86. doi: 10.1021/tx400431k. Epub 2014 Feb 26.
82	The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol. 2006 Oct;70(4):1194-203. doi: 10.1124/mol.106.025643. Epub 2006 Jul 6.
83	Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model. Arch Biochem Biophys. 2001 Jan 1;385(1):203-8. doi: 10.1006/abbi.2000.2144.
84	Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res. 2005 Apr 1;65(7):2644-52. doi: 10.1158/0008-5472.CAN-04-3544.
85	[A study on the inherited susceptibility of chromosomal damage in peripheral blood lymphocytes among coke oven workers]. Zhonghua Yu Fang Yi Xue Za Zhi. 2004 Mar;38(2):94-8.
86	Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen. Toxicology. 2007 Feb 12;230(2-3):197-206. doi: 10.1016/j.tox.2006.11.052. Epub 2006 Nov 19.
87	DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. Free Radic Res. 2011 Mar;45(3):276-92. doi: 10.3109/10715762.2010.526766. Epub 2010 Nov 1.
88	Modulation of the toxicity and macromolecular binding of benzene metabolites by NAD(P)H:Quinone oxidoreductase in transfected HL-60 cells. Chem Res Toxicol. 1999 Jun;12(6):467-75. doi: 10.1021/tx9800811.